Clinical Trial Readiness through the Establishment of a Pilot Filovirus Investigational Vaccine Reserve
Expired
The competition has expired without a winner being announced.
- Deadline
- Sep 2,Expired
- Award
- Price 20%
Brief
De Health and Digital Executive Agency (HaDEA) in België heeft behoefte aan diensten voor het opzetten van een pilotreserve van onderzoeksvaccins tegen Filovirussen (Ebola Sudan, Ebola Bundibugyo en/of Marburg) om de paraatheid voor klinische proeven bij uitbraken te waarborgen. Het contract heeft een maximale totale waarde van 16 miljoen euro en een looptijd van 4 jaar. De aanbesteding is gericht op het snel kunnen inzetten van kandidaat-vaccins voor verdere ontwikkeling tijdens een uitbraak. De gunningscriteria zijn kwaliteit (80%) en prijs (20%).
Forsknings- og utviklingsvirksomhet og tilhørende konsulenttjenester
Custom Assessment Criteria
Get answers to your bid/no-bid criteria
Set them up once and Cobrief answers them in every tender
Will you bid?
The agent sets up the bid and writes the first draft. Free for 14 days.
Award Criteria
Description
Please consult the procurement documents.
Source
No source found in the documents. Check the weight against the tender documents.
Description
Please consult the procurement documents.
Source
No source found in the documents. Check the weight against the tender documents.
Previous winners
Who are you up against?
The suppliers who have won similar contracts at Health and Digital Executive Agency (HaDEA) , HADEA - Health and Digital Executive Agency
From the notice
This call for tenders aims to ensure clinical trial preparedness for Filovirus outbreaks through the establishment of an EU-based reserve of investigational vaccines as a critical preparedness measure, given the sporadic yet high-consequence nature of these pathogens. Specifically, the call aims to establish, pilot and maintain an investigational reserve of Filovirus candidate vaccines against Ebola Sudan (SUDV), Ebola Bundibugyo (BDBV) and/or Marburg (MARV), which – in case of an outbreak – could be used to advance their development by embedding them in outbreak-associated clinical trials, facilitated through international agreements and frameworks to support such preparedness. These provisions will allow for the rapid deployment of candidate vaccines for their later-stage development. Tenderers will further have to ensure the rapid deployment of the investigational doses, subject to specific conditions being met (such as the occurrence of an outbreak and the expressed consent of the Contracting Authority).
Contact
hadea-procurement@ec.europa.eu- CompetitionType
- 73100000Main codeResearch and experimental development services
- 73120000Experimental development services